JAK2 and myeloproliferative neoplasm: The gain-of-function mutations in JAK2, i.e., mutation V617F, are often detected in patients with MPN, which includes polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).